Gastric carcinoma is the second leading cause of cancer deaths in the world. Its aetiology is closely linked to the bacterial pathogen Helicobacter pylori which is believed to induce a state of chronic inflammation that predisposes to a cascade of molecular and cellular alterations leading to carcinogenesis. Although the exact process of gastric carcinogenesis has yet to be elucidated fully, the interaction of the genetic factors with environmental factors is likely to be a significant consideration. Numerous genes and molecular pathways have been discovered to be associated with gastric adenocarcinoma and more importantly, it is now becoming possible to use some of these as means of prognostication and targeted therapy. This review will outline our current understanding of the aetiology and molecular genetics of gastric adenocarcinoma and its current clinical applications.
IntroductIon
Despite a major decline in incidence and mortality rates over the last 50 years, gastric cancer remains the fourth most common cancer and the second leading cause of cancer death in the world 1 . Gastric cancer in Singapore is the fourth most common malignancy and the third highest cause of cancerrelated mortality in both males and females 2 . As gastric carcinoma is often diagnosed at a late stage, conventional treatment in the form of surgery, radiation and chemotherapy results in overall 5-year survival rates of less than 30% 3 .
The rapid advances in genomic and molecular techniques in the last 2 decades have yielded new insights into the processes of gastric carcinogenesis. It is now known that different pathways lead to intestinal-and diffuse-type gastric cancer. The molecular heterogeneity of gastric cancer is also largely due to a constant and complex interplay of genetic and environmental factors. This review will attempt to summarise the major mechanisms and risk factors that contribute to the development of gastric adenocarcinoma.
PAtholoGy
More than 90% of gastric cancers (GC) are adenocarcinomas with lymphomas and stromal tumours accounting for the rest. The majority of adenocarcinomas are sporadic although clustered cases can occur whether due to an inherited genetic mutation and/or shared environmental factors.
It is generally recognised that there are 2 main histological types of gastric carcinoma as first described in 1965 4 . The Lauren classification defines these as the intestinal type which is characterised by the metaplastic transformation of gastric-type mucosa into an intestinal type with abundant goblet cells; and, the diffuse type which comprises cells that have defective adhesion properties and typically appear as poorly differentiated signet ring cells. Both types may also co-exist thereby giving rise to a third entity of "mixed" pathology.
The intestinal type is the more common variant and it is usually associated with chronic atrophic gastritis and multifocal gastric atrophy which then progresses to metaplasia followed by dysplasia before manifesting overt carcinoma 5 . In contrast, the diffuse type cancers do not show this histological and temporal patten of development. Intestinal type cancer is more frequent in older patients in high-risk endemic regions whereas the diffuse type has a higher incidence in younger patients in low-risk areas and indeed may sometimes be hereditary. This observation supports the notion that the "nurture" component predominates in intestinal type GC whereas the "nature" component is the stronger factor in diffuse-type GC 6 .
AetIoloGy
It is now generally accepted that gastric cancer arises from gene-environment interactions 7, 8 . The degree of influence of genetic factors versus environmental factors in gastric carcinogenesis appears to depend on the pathological type of cancer. The multi-step progression of intestinal type cancer suggests that environmental factors have a greater role; and this is supported by its close association with risk factors such as high salt intake, smoked or nitrated foods, low intake of fruits and vegetables and H. pylori infection 9 . The pathogenesis of diffuse-type cancer is less well understood although it is also associated with H. pylori infection 10 . The existence of lineages of hereditary diffuse gastric cancer (HDGC) such as the family of Napoleon Bonaparte 11 indicates the likelihood that genetic factors are the major determinant in diffuse-type cancer. Several other inherited conditions such as familial adenomatous polyposis (FAP), hereditary non-polyposis colon cancer (HNPCC), Peutz-Jeghers syndrome, and Li-Fraumeni syndrome also have strong associations with gastric adenocarcinoma 12 .
With the exception of genetic syndromes, by far the strongest established risk factor for gastric cancer is H. pylori infection. Approximately 70-80% of gastric cancers are associated with H. pylori infection 13 . Although H. pylori has been classified as a WHO Class I carcinogen since 1994, the exact mechanism underlying malignant transformation remains to be clarified. The complexity of the underlying processes is demonstrated in the divergent responses of individuals to H. pylori infection. The majority of patients exhibit a mild pangastritis; a second group develops antral gastritis and duodenitis with hyperchlorydia; and, a third group experience gastritis mainly in the body of the stomach which eventually leads to hypochlorydia and atrophic gastritis which are precursors of intestinal type gastric cancer 14 . The markedly differing responses to H. pylori are attributed to a combination of bacterial virulence factors, host genetic susceptibility and environmental conditions 15 .
H. pylori strains that possess the cagA, vacA, and babA virulence-associated genes carry the highest risk for gastric cancer 16 . The cagA gene induces activation of the ERK/MAP (extracellular signal-regulated/ mitogen-activated protein) kinase cascade that leads to expression of the c-fos and c-jun protooncogenes 17 . CagA protein is phosphorylated by cellular tyrosine phosphatase. Phosphorylated cagA protein binds to SHP2 which eventually leads to IL-8 secretion thus activating neutrophils. CagA protein has also been demonstrated to be the first bacterial oncoprotein that acts in human cells. Phosphorylated cagA protein binds to and induces deregulation of SHP-tyrosine phosphatase, which itself is another oncoprotein involved in human malignancies 18, 19 . H. pylori strains containing vacA induce vacuole formation and apoptosis in gastric epithelial cells leading to ulcer formation 20 . The BabA protein induces tighter adhesion to gastric epithelial cells leading to more severe disease 16 .
The host inflammatory response to chronic H. pylori infection is a major component of intestinal type gastric carcinogenesis. Cytokines such as IL-1β and TNF-α are potent inhibitors of acid secretion and also affect gastrin secretion 18 . Allelic polymorphisms are known to affect the degree of cytokine response to infections and chronic inflammation. IL-1β gene polymorphisms have been associated with increased incidence of hypochlorydia and atrophic gastritis in first-degree relatives of British gastric cancer patients 19 . IL-10 is an anti-inflammatory cytokine that down-regulates IL-1β, TNF-α and other pro-inflammatory cytokines. A relative deficiency of IL-10 may result in a pronounced inflammatory response with a higher risk of gastric cancer 20 . Allelic polymorphisms of IL-8, a potent chemokine for neutrophils with effects on cell proliferation, have also been shown to be associated with gastric cancer 21 .
The model for intestinal-type gastric carcinogenesis in a patient with H. pylori infection would therefore involve a genotype comprising pro-inflammatory cytokine alleles that eventually lead to a constantly inflamed and hypochlorydic gastric mucosa. The Proceedings of Singapore Healthcare  Volume 19  Number 1  2010 bacterial effect on mucosal inflammation would be exacerbated by the presence of cagA, vacA, and babA gene products in the resident H. pylori . Once gastric acidity has been reduced, other bacteria may proliferate in the stomach leading to increased oxidative activity and the production of nitrosamines which can inflict further DNA damage.
GenoMIc MechAnIsMs of GAstrIc cArcInoGenesIs
The genomic mechanisms that cause genetic alterations leading to gastric cancer are still incompletely understood. The genetic and epigenetic changes in gastric cancer appear to be largely due to 3 general mechanisms of genomic instability 9 . The chromosomal instability mechanism has been associated with mutations in genes such as BRCA1 and BRCA2 (double-strand break repair genes) that control the structural integrity of chromosomes 22, 23 . Chromosomal rearrangements may be accompanied by deletions or gains of specific oncogenes or tumour suppressor genes leading to changes in their activity thereby promoting carcinogenesis 12, 24 . Genes which are affected by chromosomal instability include p53, veGF, and CDH1. Microsatellites are short DNA sequence repeats that occur throughout the genome. The microsatellite instability (MSI) mechanism in gastric cancer is characterised by hypermethylation (rather than mutation as in HNPCC) of one or more of the mismatch repair genes, such as MLH1 or MSH2, leading to different number of DNA sequence repeats in tumour cells. This could result in frameshift mutations leading to errors in translation of DNA into proteins products. An example of a gene affected by MSI frameshift mutation is TGFBR2 27, 28 . MSI-positive gastric cancers are more likely to be antral tumours, less prone to p53 mutations and have a generally better prognosis 25 . A third mechanism involves epigenetic changes through methylation of cytosine-phosphate-guanine (CpG) islands (regions where cytosine and guanine bases are in sequence on the same strand of DNA). Abnormal methylation of CpG islands causes transcriptional silencing of genes such as CDH1 or MLH1 that could eventually lead to malignancy 26, 27 . The prevalence and co-existence of these 3 types of genomic instability is variable between intestinal and diffuse gastric cancers and within each individual subtype.
GenetIc AlterAtIons of GAstrIc cArcInoGenesIs
The development of gastric cancer is attributed to the accumulation of multiple gene abnormalities. These genetic aberrations include oncogene activation, tumour suppressor gene inactivation and telomerase reactivation 28 . Although each gastric cancer may have multiple genetic defects, no specific sequence of changes has yet been identified as pathognomonic for gastric cancer; therefore most of these genetic alterations may in fact only be associated with, rather than actually be causal of, the pathogenesis of gastric cancer.
A variety of proto-oncogenes are activated in gastric cancer and there is considerable variation between diffuse and intestinal type tumours. The membrane receptor c-erbB-2 (HeR2/neu) is overexpressed in approximately 20% of intestinal-type gastric cancers but not in diffuse type tumours 29 . It has been associated with a shorter diseasespecific and overall survival as well as with liver metastases 30, 31 .The K-sam oncogene which encodes for a keratinocyte growth factor has also been shown to be involved in gastric carcinogenesis 32, 33 . It is highly expressed in 53% of diffuse-type cancers but is notably normal in intestinal type tumours 34 . The marked difference in expression of c-erbB-2 and K-sam has raised the possibility that they may be useful as prognostic biomarkers of intestinal and diffuse type carcinomas respectively 35 . Another notable proto-oncogene that is frequently over-expressed in gastric cancer is c-met which encodes a tyrosine kinase receptor for hepatocyte growth factor. It is amplified in 19.2% of intestinal-type cancers and in 38.5% of diffuse-type cancers 36 and is generally associated with a poorer prognosis.
Many tumour suppressor genes have been shown to be inactivated in gastric cancers, of which the most notable are p53, APC, CDH1, p16, FHiT, DCC and RUNX3. The p53 gene is frequently inactivated in gastric carcinoma by mutations, loss of heterozygosity (LOH) or deletions 14 . It is altered in intestinal metaplasia (37.5%), dysplasia (58.3%) and overt carcinoma (66.7%), of both the diffuse-and intestinal-type cancers 37, 38 . The p53 protein is essential in regulating the cell cycle by its ability to induce growth arrest, activate DNA repair proteins and initiate apoptosis. One defective allele of p53 is inherited in the Li-Fraumeni syndrome in which several independent tumours typically Proceedings of Singapore Healthcare  Volume 19  Number 1  2010 develop in early adulthood. Mutations of the APC gene on chromosome 5q are the hallmark of familial adenomatous polyposis coli and these patients have a higher lifetime risk of developing gastric cancer. Although APC gene mutation and LOH are seen in approximately 60% of sporadic intestinal-type cancers, they are rare in diffuse-type cancers 39 . Wild-type APC protein binds cytoplasmic β-catenin, preventing it from entering the nucleus where it acts as a transcription factor for genes that drive cell proliferation. The accumulation of cellular β-catenin from an APC defect or β-catenin gene (CTNNB1) mutation eventually leads to abnormal cellular growth and proliferation. The RUNX3 protein is part of a heterodimeric transcription factor complex that either activates or suppresses gene transcription. It operates downstream of the TGF-β signalling pathway and modulates apoptosis and cellular proliferation. Approximately 45-60% of gastric cancers exhibit loss of RUNX3 expression due to gene deletion or promoter methylation 40, 41 .
The CDH1 tumour suppressor gene codes for the protein E-cadherin which is a homophilic cell-cell adhesion glycoprotein. Loss of E-cadherin function results in increased cellular proliferation, tissue invasion and cellular migration to distant metastasis. CDH1 mutations are not characteristic of intestinaltype gastric cancers but occur in 50% of sporadic diffuse-type carcinomas 42 . Germline mututions of CDH1 account for up to one-third of families with hereditary diffuse gastric cancer (HDGC) 43 . Mutations in other genes (as yet unknown) are likely to be responsible for the other two-thirds. HDGC is inherited in an autosomal dominant manner with penetrance of approximately 80% and an average age of onset in the fourth decade of life 44 . Patients with CDH1-HDGC remain normal until the second allele is inactivated, which usually occurs via promoter methylation 45 .
Telomeres are repetitive sequences of DNA (TTAGGG) at the ends of chromosomes that gradually shorten with each successive mitotic division in normal cells, thus limiting the number of times each cell may divide before it senesces 46 . Reactivation of telomerase in stem cells and malignant cells prevents telomere shortening by adding new copies of the TTAGGG tandem repeat to the ends of chromosomes 47, 48 . Human telomerase reverse transcriptase (hTERT) is one of the components present in the telomerase complex.
Elevated expression of hTERT has been detected in the nuclei of gastric cancer cells, suggesting that it has an important role in gastric carcinogenesis 49 .
MoleculAr fActors of GAstrIc cAncer InvAsIon And MetAstAsIs
Gastric cancer is a highly aggressive disease with rapid patterns of spread resulting in many patients being diagnosed at a late stage. The mechanisms for this aggressive phenotype remain poorly understood although it is probably attributable to genetic and molecular factors that control cell growth, differentiation and adhesion 28 . Although the early stages of carcinogenesis are likely initiated by the activation of oncogenes and the inactivation of tumour suppressor genes, it is thought that these dysfunctional activities are then aggravated by the development of a "stress" microenvironment such as hypoxia, acidosis and free radical production, thus advancing the carcinogenic process into uncontrolled tumour growth 50 . Some over-expressed transcription factors and growth factors include NF-κB, CDX1, CDX2, EGF, VEGF, EGFR and TGF-α 28 . The action of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) generates signalling molecules such as nitric oxide and prostaglandins that promote tumour angiogenesis, tumour progression and result in poorer patient survival 51, 52 .
GAstrIc cAncer steM cells
Cancer stem cells are self-renewing multipotent cells within tumours that initiate tumour growth and have metastatic potential 53 . Although the normal gastric stem cell has yet to be definitively identified, it has been presumed that in the corpus of the stomach, it is located in the isthmus of the gastric glands from which it gives rise to differentiated daughter cells via bidirectional migration patterns 54 . In the antrum of the stomach, the stem cells are believed to be located at the bottom of the glands from which daughter cells migrate towards the surface unidirectionally 55 . Another possible source for gastric cancer stem cells from outside the stomach is the bone marrow. Bone-marrow-derived cells (BMDC) were elegantly shown in H. pylori-infected mice to repopulate the stomach before progressing through metaplasia and dysplasia to intra-epithelial cancer 56 .
clInIcAl APPlIcAtIons
The application of research findings to patient care is commonly found in the areas of molecular diagnosis, prognostication and therapeutics. For example, the differential expression of c-erbB-2 and K-sam has led to the possibility of using them as prognostic markers for intestinal and diffuse type cancer respectively 35 . VEGF-positive tumours have also been shown to have a worse prognosis than VEGF-negative tumours 35 . CDH1 and E-cadherin are already in use as screening tools for HDGC and the diagnostic and prognostic strength of the association with diffuse cancer is sufficient to propose "prophylactic" total gastrectomy for affected family members 57 . The resected stomachs almost invariably show microscopic intramucosal signet cell cancer not detected by conventional means 58 . Targetprotein-based cancer therapy is also possible using monoclonal antibodies, small molecules or anti-sense oligonucleotides for inhibition of specific proliferative factors 59 . Agents like imatinib and trastuzumab have been developed for chronic myeloid leukaemia and breast cancer, and although no specific drug has yet to be developed for gastric cancer, some of the existing agents have shown promise in the treatment of advanced disease. Trastuzumab (Herceptin) is a monoclonal antibody that binds to the HER2 transmembrane receptor tyrosine kinase protein thus inhibiting cellular proliferation. It has been shown to have a statistically significant effect on prolonging overall survival (13.5 months vs 11.1 months at 17.1 months follow-up) in a recent trial for the treatment of advanced gastric cancer (ToGa) [60] [61] [62] . A clinical trial involving trastuzumab in combination with TS-1 and cisplatin in advanced gastric cancer patients is currently ongoing in the National Cancer Centre of Singapore. Other agents that have been investigated include bevacizumab (Avastin) and borteozomib (Velcade) although neither has shown as much promise as trastuzumab. Preliminary results of the AVAGAST Phase III trial suggested that bevacizumab had no beneficial impact on the overall survival of metastatic gastric cancer patients when added to Xeloda and cisplatin chemotherapy.
conclusIon
The ongoing research on the molecular aspects of gastric cancer has yielded a wealth of knowledge that is finally beginning to have clinical applications in the diagnosis, prognostication and therapy of this lethal disease. Although our understanding of the disease is still far from comprehensive, further work in the exciting area of cancer stem cells and cancer pathways is likely to provide us with novel methods to detect and treat gastric carcinoma in future.
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